We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Desperate Muscle Cells Produce Nerve Regenerating MicroRNA

By LabMedica International staff writers
Posted on 21 Dec 2009
Neuroscientists are investigating the possible therapeutic applications of a class of microRNA (miRNA) produced by damaged muscle cells in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease).

ALS is a neurodegenerative disease with no known cause characterized by loss of motor neurons, denervation of target muscles, muscle atrophy, and paralysis. More...
As the disease progresses and muscle tissues begin to degenerate due to lack of nerve stimulation, muscle cells produce various molecules aimed at stimulating regeneration of nerves.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) studied one of these molecules, the microRNA miR-206. They reported in the December 11, 2009 issue of the journal Science that the skeletal muscle specific miRNA-206 was a key regulator of nerve regeneration signaling, and that it was dramatically induced in a mouse model of ALS. Mice that were genetically deficient in miR-206 formed normal neuromuscular synapses during development, but deficiency of miR-206 in the ALS mouse model accelerated disease progression. MiR-206 was required for efficient regeneration of neuromuscular synapses after acute nerve injury, which, thought the investigators, probably accounted for its salutary effects in ALS.

"MiR-206 seems to sense nerve injury and promote regeneration," said senior author Dr. Eric Olson, professor of molecular biology at the University of Texas Southwestern Medical Center. "While miR-206 initially prompts nearby surviving nerves to send new branches to the muscles, it only delays the inevitable. Our findings correlate with the observation in ALS patients that the disease is nearly asymptomatic until a large fraction of motor neurons has died, at which point the few remaining ones cannot compensate sufficiently. These results provide a new perspective on the mechanisms of ALS. Because miR-206 only exists in skeletal muscle, a drug based on it might not affect other tissues. That limits its risk of side effects and is a key part of its appeal as a potential therapy."

Related Links:
University of Texas Southwestern Medical Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.